Oleg Gluz

6.7k total citations · 1 hit paper
142 papers, 2.4k citations indexed

About

Oleg Gluz is a scholar working on Cancer Research, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Oleg Gluz has authored 142 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 102 papers in Cancer Research, 93 papers in Oncology and 60 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Oleg Gluz's work include Breast Cancer Treatment Studies (93 papers), HER2/EGFR in Cancer Research (51 papers) and Advanced Breast Cancer Therapies (51 papers). Oleg Gluz is often cited by papers focused on Breast Cancer Treatment Studies (93 papers), HER2/EGFR in Cancer Research (51 papers) and Advanced Breast Cancer Therapies (51 papers). Oleg Gluz collaborates with scholars based in Germany, Switzerland and United States. Oleg Gluz's co-authors include Nadia Harbeck, Ulrike Nitz, C Liedtke, Lajos Pusztai, Nina Gottschalk, Matthias Christgen, Hans Kreipe, Ronald Kates, Rachel Wuerstlein and Cornelia Liedtke and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Oleg Gluz

129 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Triple-negative breast cancer—current status and future directions

2009 513 citations Oleg Gluz, C Liedtke et al. Annals of Oncology profile →

Peers

Countries citing papers authored by Oleg Gluz

Since Specialization

Citations

This map shows the geographic impact of Oleg Gluz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Oleg Gluz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Oleg Gluz more than expected).

Fields of papers citing papers by Oleg Gluz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Oleg Gluz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Oleg Gluz. The network helps show where Oleg Gluz may publish in the future.

Co-authorship network of co-authors of Oleg Gluz

This figure shows the co-authorship network connecting the top 25 collaborators of Oleg Gluz. A scholar is included among the top collaborators of Oleg Gluz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Oleg Gluz. Oleg Gluz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Clinicopathological Characteristics of a Distinct Tumor Phenotype: Invasive Lobular Carcinoma With Tubular Elements in the West German Study Group ADAPTcycle Trial 2025 ·Laboratory Investigation ·(unknown), (unknown), Katarzyna Jóźwiak, (unknown), (unknown), Mieke Raap, Stephan Bartels, Henriette Christgen, (unknown), Petra Hillmann, Ulrich Lehmann, Oleg Gluz, Monika Graeser, (unknown), Christine zu Eulenburg, Nadia Harbeck, Hans Kreipe, Matthias Christgen	2
2	Multiomic factor analysis for pathologic complete response (pCR) after 12 weeks of pembrolizumab + trastuzumab + pertuzumab in HER2-enriched (HER2-E) early breast cancer (eBC) in the Keyriched-1 trial. 2024 ·Journal of Clinical Oncology ·Monika Graeser, Oleg Gluz, Peter Schmid, Katarzyna Jóźwiak, Friedrich Feuerhake, Valery Volk, (unknown), (unknown), Mattea Reinisch, Kerstin Lüedtke-Heckenkamp, Andreas D. Hartkopf, Felix Hilpert, Michael Braun, Jens‐Uwe Blohmer, Matthias Christgen, Hans Kreipe, Ulrike Nitz, Enrico Pelz, Nadia Harbeck, Sherko Küemmel	1
3	Neoadjuvant dynamic marker-adjusted personalized therapy comparing trastuzumab-deruxtecan versus pacli-/docetaxel + carboplatin + trastuzumab + pertuzumab in HER2+ early breast cancer: WSG-ADAPT-HER2-IV. 2024 ·Journal of Clinical Oncology ·Nadia Harbeck, Michael Braun, Oleg Gluz, Peter Schmid, Monika Graeser, Andreas D. Hartkopf, Oliver Hoffmann, (unknown), Silke Polata, (unknown), Raquel von Schumann, (unknown), (unknown), Matthias Zaiß, (unknown), Iris Scheffen, Matthias Christgen, Hans Kreipe, Ulrike Nitz, Sherko Küemmel	2
4	193P Efficacy of sacituzumab govitecan versus treatment of physician’s choice in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: A meta-analysis of TROPiCS-02 and EVER-132-002 trials 2024 ·ESMO Open ·Oleg Gluz, Binghe Xu, (unknown), (unknown), (unknown), (unknown), Gianluca Baio, Ajay Sharma, Baljinder Singh, (unknown)	1
5	120TiP Premenopausal women with breast cancer optimally treated with OFS (PROOFS) 2023 ·ESMO Open ·(unknown), Oleg Gluz, Monika Graeser, Ulrike Nitz, (unknown), Nadia Harbeck, Sherko Küemmel, Christine zu Eulenburg, Mathias Warm, Rachel Wuerstlein	1
6	Favorable impact of therapy management by an interactive eHealth system on severe adverse events in patients with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer treated by palbociclib and endocrine therapy 2023 ·Cancer Treatment Reviews ·Nadia Harbeck, Ronald Kates, Timo Schinköthe, (unknown), Rachel Wuerstlein, Tom Degenhardt, Diana Lüftner, (unknown), Oliver Hoffmann, Ralf Lorenz, Thomas Decker, Mattea Reinisch, Thomas Göhler, Peter Staib, Oleg Gluz, Peter A. Fasching, Marcus Schmidt	6
7	Molecular Profiling in Early ER + Breast Cancer to Aid Systemic Therapy Decisions 2023 ·Current Oncology Reports ·Oleg Gluz, Monika Graeser	4
8	The impact of anthracyclines in intermediate and high-risk HER2-negative early breast cancer—a pooled analysis of the randomised clinical trials PlanB and SUCCESS C 2022 ·British Journal of Cancer ·Amelie de Gregorio, Wolfgang Janni, Thomas W. P. Friedl, Ulrike Nitz, Brigitte Rack, Andreas Schneeweiß, Ronald Kates, Tanja Fehm, Hans Kreipe, Matthias Christgen, Sherko Kümmel, Elisabeth Trapp, Rachel Wuerstlein, Andreas D. Hartkopf, Michael Clemens, Toralf Reimer, Lothar Häberle, Peter A. Fasching, Oleg Gluz, Nadia Harbeck	23
9	Immune Markers and Tumor-Related Processes Predict Neoadjuvant Therapy Response in the WSG-ADAPT HER2-Positive/Hormone Receptor-Positive Trial in Early Breast Cancer 2021 ·Cancers ·Nadia Harbeck, Raquel von Schumann, Ronald Kates, Michael Braun, (unknown), Claudia Schumacher, Jochem Potenberg, Wolfram Malter, Doris Augustin, Bahriye Aktas, Helmut Forstbauer, Joke Tio, Eva‐Maria Grischke, (unknown), Cornelia Liedtke, Sanne Lysbet de Haas, Regula Deurloo, Rachel Wuerstlein, Hans Kreipe, Oleg Gluz	10
10	Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1 2020 ·Molecular Cancer Research ·Vineesh Indira Chandran, Ann‐Sofie Månsson, (unknown), Myriam Cerezo-Magaña, Björn Nodin, Bharat Joshi, Neelima Koppada, Ola M. Saad, Oleg Gluz, Karolin Isaksson, Signe Borgquist, Karin Jirström, Ivan R. Nabi, Helena Jernström, Mattias Belting	25
11	Updated Survival Analysis after a Median Follow-up of 12 Years of an Anthracycline-Containing Adjuvant Prospective Multicentre, Randomised Phase III Trial on Dose-Dense Chemotherapy in Primary Node-Positive, High-Risk Breast Cancer Patients 2018 ·Breast Care ·Mattea Reinisch, Oleg Gluz, Beyhan Ataseven, Jens‐Uwe Blohmer, (unknown), (unknown), A. Kohls, (unknown), (unknown), (unknown), (unknown), Alexander Traut, Sherko Kümmel	2
12	First-line Bevacizumab-containing Therapy for HER2-negative Metastatic Breast Cancer: Final Results from a Prospective German Study. 2016 ·PubMed ·Andreas Schneeweiß, Frank Förster, Hans Tesch, Bahriye Aktas, Oleg Gluz, Matthias Geberth, (unknown), (unknown), Claudia Schumacher, (unknown), Claudia Kiewitz, (unknown), Marcus Schmidt	10
13	Prospective WSG phase III PlanB trial: Clinical outcome at 5 year follow up and impact of 21 Gene Recurrence Score result, central/local-pathological review of grade, ER, PR and Ki67 in HR+/HER2-high risk node-negative and -positive breast cancer 2016 ·European Journal of Cancer ·Oleg Gluz, (unknown), (unknown), (unknown), Michael Clemens, Stefan Kraemer, Benno Nuding, Bahriye Aktas, Sherko Küemmel, Toralf Reimer, Fatemeh Lorenz-Salehi, Petra Krabisch, Marianne Just, Doris Augustin, C Liedtke, Cecilia Svedman, S. Shak, Rachel Wuerstlein, (unknown), Nadia Harbeck	5
14	Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial 2016 ·Annals of Oncology ·Oleg Gluz, C Liedtke, Jens Huober, (unknown), Ronald Kates, Hans Kreipe, Arndt Hartmann, Enrico Pelz, Ramona Erber, Svjetlana Mohrmann, Volker Möbus, Doris Augustin, G. M. Hoffmann, Christoph Thomssen, F. Jänicke, Marion Kiechle, D. Wallwiener, W. Kühn, Ulrike Nitz, Nadia Harbeck	10
15	Trastuzumab emtansine (T-DM1) renders HER2 ⁺ breast cancer highly susceptible to CTLA-4/PD-1 blockade 2015 ·Science Translational Medicine ·Philipp Müller, Matthias Kreuzaler, Tarik A. Khan, Daniela S. Thommen, Kea Martin, Katharina Glatz, Spasenija Savic, Nadia Harbeck, Ulrike Nitz, Oleg Gluz, Michael von Bergwelt‐Baildon, Hans Kreipe, Sai T. Reddy, Matthias Christgen, Alfred Zippelius	269
16	Final results from the prospective phase III WSG-ARA trial: impact of adjuvant darbepoetin alfa on event-free survival in early breast cancer 2013 ·Annals of Oncology ·Ulrike Nitz, Oleg Gluz, I. Zuna, C. Oberhoff, Toralf Reimer, Claudia Schumacher, John Hackmann, M Warm, Christoph Uleer, Volker Runde, (unknown), (unknown), Doris Augustin, Ronald Kates, Nadia Harbeck	15
17	Personalized treatment of early-stage breast cancer: Present concepts and future directions 2010 ·Cancer Treatment Reviews ·Nadia Harbeck, Marwa Rashad Salem, Ulrike Nitz, Oleg Gluz, Cornelia Liedtke	41
18	Nuclear karyopherin α2 expression predicts poor survival in patients with advanced breast cancer irrespective of treatment intensity 2008 ·International Journal of Cancer ·Oleg Gluz, Peter J. Wild, (unknown), (unknown), Evelyn Ting, Svjetlana Mohrmann, (unknown), Edgar Dahl, Thomas J. Fuchs, Alexander Herr, Andreas Gäumann, (unknown), Christopher Poremba, Ulrike Nitz, Arndt Hartmann	66
19	Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial 2008 ·Annals of Oncology ·Oleg Gluz, Ulrike Nitz, Nadia Harbeck, Evelyn Ting, Ronald Kates, Alexander Herr, Walter Lindemann, Christian Jackisch, Wolfgang E. Berdel, Hartmut Kirchner, Bernd Metzner, Franziska Werner, (unknown), Michael Frick, Christopher Poremba, (unknown), Svjetlana Mohrmann	84
20	Protein Expression Profiling in High-Risk Breast Cancer Patients Treated with High-Dose or Conventional Dose–Dense Chemotherapy 2007 ·Clinical Cancer Research ·(unknown), Evelyn Ting, Oleg Gluz, Alexander Herr, Svjetlana Mohrmann, Helene Geddert, Achim Rody, Karl‐Ludwig Schaefer, Stephan Baldus, Arndt Hartmann, Peter J. Wild, (unknown), Helmut E. Gabbert, Ulrike Nitz, Christopher Poremba	57

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact